Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Conditions:   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Adenocarcinoma;   Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone
Sponsors:   Rashmi Verma, MD;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 4, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments